Postmenopausal Osteoporosis Monitoring Schedule: Exactly When and How Often to Test

Why Estrogen Loss Changes Everything About Your Bones

Bone loss after menopause is not a slow, steady drip. In the first two to three years after your final menstrual period, you may lose 3 to 5 percent of your bone mineral density (BMD) per year, a rate that then settles to about 1 to 2 percent annually for the rest of your postmenopausal life. The Menopause Society (NAMS) 2023 position statement identifies estrogen deficiency as the primary driver of this accelerated phase.

The Physiology Behind the Numbers

Estrogen suppresses osteoclast activity, the cells that break bone down. When estrogen drops at menopause, osteoclasts become overactive relative to osteoblasts, the cells that build bone. The net result is a negative bone remodeling balance that is measurable on DEXA within months of estrogen withdrawal.

This is not just a postmenopausal problem. Women who enter surgical menopause before age 45 face the same biology earlier, and often more abruptly. A 2019 cohort study in the Journal of Bone and Mineral Research found that women who underwent bilateral oophorectomy before age 45 had significantly lower BMD and higher fracture risk at age 60 compared with women with natural menopause, underscoring the need for earlier and more frequent monitoring in that group.

Who Loses the Most Bone?

Certain women lose bone faster than others. Risk accelerators include low body weight (BMI <20), smoking, heavy alcohol use, long-term glucocorticoid use, early menopause, a family history of hip fracture, and conditions such as rheumatoid arthritis, celiac disease, or a history of anorexia nervosa. The AACE/ACE 2020 Clinical Practice Guidelines for Postmenopausal Osteoporosis list these as drivers that can move a woman into a high-risk monitoring tier.

The Exact Baseline Monitoring Schedule by Life Stage

The monitoring schedule is not one-size-fits-all. Where you are in your reproductive life determines when your first scan should happen and how often you repeat it.

Perimenopause (Before Your Final Period)

Routine DEXA is not recommended during perimenopause for low-risk women. But if you have two or more major risk factors, such as a fragility fracture after age 40, long-term corticosteroid use, or a condition causing secondary osteoporosis, a baseline scan during perimenopause is clinically reasonable. ACOG Practice Bulletin 129 supports this individualized approach.

Early Postmenopause (Ages 50-64)

For women in this window, DEXA is indicated when any of the following apply:

• A fragility fracture has already occurred
• BMI is <20 kg/m²
• You take or have taken oral glucocorticoids for more than 3 months
• A medical condition associated with bone loss is present (PCOS with hyperandrogenism, hyperthyroidism, malabsorption syndromes)
• Your FRAX 10-year major osteoporotic fracture probability exceeds 9.3 percent (the USPSTF threshold for considering treatment)

Age 65 and Older

The USPSTF recommends DEXA for all women age 65 and older regardless of symptoms or risk factors. This is the one universal, age-based trigger. If your first scan at 65 shows normal bone density (T-score above -1.0), guidelines support a repeat interval of 10 to 15 years unless risk factors change. Women with osteopenia (T-score between -1.0 and -2.5) need rescreening every 2 to 5 years depending on severity.

Diagnosing Postmenopausal Osteoporosis: What the Numbers Actually Mean

Osteoporosis is a DEXA T-score at or below -2.5 at the lumbar spine, femoral neck, or total hip, per WHO diagnostic criteria. Osteopenia sits between -1.0 and -2.5. Normal is above -1.0.

T-Score vs. Z-Score

Your T-score compares you to a young adult reference population. Your Z-score compares you to women your own age. In postmenopausal women, the T-score drives treatment decisions. A Z-score below -2.0, however, is a signal that bone loss is worse than expected for age and prompts investigation for secondary causes.

FRAX: Adding Fracture Probability to the Picture

A T-score alone does not fully capture fracture risk. The FRAX tool, developed from data including the Rotterdam Study and Dubbo Osteoporosis Epidemiology Study, combines BMD with clinical risk factors to estimate your 10-year probability of a major osteoporotic fracture (spine, hip, forearm, or shoulder) and hip fracture specifically. The National Osteoporosis Foundation (NOF) and AACE recommend initiating pharmacologic treatment when the 10-year hip fracture probability exceeds 3 percent or the major fracture probability exceeds 20 percent, even if the T-score is only in the osteopenia range.

FRAX should be recalculated every 2 years for untreated women with low bone mass. This is a monitoring step that many clinicians skip, and it matters.

Vertebral Fracture Assessment (VFA)

Standard DEXA machines can now perform a lateral spine image called a vertebral fracture assessment. Up to 25 percent of postmenopausal women have at least one asymptomatic vertebral fracture, according to data from the Study of Osteoporotic Fractures (SOF). A single vertebral fracture more than doubles subsequent fracture risk. VFA is recommended at the time of your initial DEXA if you are postmenopausal and over 70, have lost more than 4 cm of height, or have a T-score below -2.0.

On-Treatment DEXA Monitoring: Drug by Drug

Once you start a bone-protective medication, the monitoring schedule changes based on what you are taking, your response, and whether a drug holiday applies.

Bisphosphonates (Alendronate, Risedronate, Zoledronic Acid, Ibandronate)

Bisphosphonates are the most prescribed first-line agents for postmenopausal osteoporosis. The HORIZON Key Fracture Trial showed that annual intravenous zoledronic acid (5 mg) reduced hip fracture risk by 41 percent over 3 years compared with placebo. Alendronate (70 mg weekly orally) produced similar vertebral fracture risk reductions in the FIT trial.

Monitoring timeline on bisphosphonates:

• Repeat DEXA at 1 to 2 years after starting to confirm BMD response
• If T-score improves or stabilizes and fracture risk is low-to-moderate, a drug holiday at 3 to 5 years is reasonable for oral bisphosphonates
• After IV zoledronic acid, the drug holiday is considered at 3 infusions (3 years)
• During a drug holiday, repeat DEXA every 2 to 3 years; restart treatment if T-score drops below -2.5 or a new fracture occurs

The AACE/ACE 2020 guidelines specify that women at high fracture risk (T-score at or below -2.5, prior vertebral or hip fracture) should not take a bisphosphonate holiday without close monitoring.

Denosumab (Prolia, 60 mg SC every 6 months)

Denosumab requires a fundamentally different monitoring approach. Unlike bisphosphonates, denosumab's effect on bone does not persist after you stop taking it. The FREEDOM Extension trial showed continued BMD gains at 10 years, but stopping denosumab causes rapid bone loss within 12 months, with rebound vertebral fracture risk that can be higher than pre-treatment levels.

Monitoring timeline on denosumab:

• Repeat DEXA every 2 years while on therapy
• Serum calcium and renal function before each injection (every 6 months)
• If you need to stop denosumab for any reason, transition immediately to a bisphosphonate to prevent rebound bone loss. This is not optional.
• DEXA at 6 to 12 months after stopping denosumab to detect rapid loss

Romosozumab (Evenity, 210 mg SC monthly for 12 months)

Romosozumab is a sclerostin inhibitor used for high-risk women, typically those who have already fractured on another therapy. The ARCH trial demonstrated superiority over alendronate in reducing clinical fractures at 12 months. Romosozumab carries a boxed warning for cardiovascular risk.

Monitoring on romosozumab:

• Treatment is fixed at 12 months; DEXA is typically repeated at the end of the 12-month course
• Transition to an antiresorptive (bisphosphonate or denosumab) immediately after completing romosozumab; gains are lost without follow-on therapy
• Serum calcium at baseline and as clinically indicated

Teriparatide and Abaloparatide (Anabolic Agents)

Both are daily subcutaneous injections limited to 24 months (teriparatide) or 18 months (abaloparatide). The key teriparatide trial by Neer et al. In the NEJM (2001) showed a 65 percent reduction in new vertebral fractures. DEXA is repeated at the end of the treatment course, and an antiresorptive must follow to maintain gains.

Laboratory Monitoring: What to Check and How Often

Bone density imaging tells only part of the story. Labs catch secondary causes and drug-related complications.

At Diagnosis (Baseline)

Order these at your first osteoporosis visit:

• Serum 25-hydroxyvitamin D (target: 30 to 50 ng/mL for fracture prevention)
• Serum calcium and albumin
• Complete metabolic panel (renal function, phosphorus, magnesium)
• Thyroid-stimulating hormone (TSH): subclinical hyperthyroidism accelerates bone loss
• Complete blood count
• Serum protein electrophoresis if multiple myeloma is a concern (unexplained vertebral fractures, age over 60)
• 24-hour urine calcium if hypercalciuria is suspected

Annual Labs on Treatment

At minimum, repeat serum 25-hydroxyvitamin D, calcium, and renal function annually. Women on denosumab need calcium and renal function before every injection (every 6 months). Women on teriparatide or abaloparatide need calcium checked at baseline and periodically throughout.

Bone turnover markers (BTMs) such as serum CTX (C-telopeptide) and P1NP (procollagen type I N-terminal propeptide) are not universally standard but are recommended by the Endocrine Society's 2019 Clinical Practice Guideline as a way to assess treatment adherence and response between DEXA scans. A suppressed CTX 3 to 6 months after starting a bisphosphonate suggests the drug is working; a CTX that remains elevated may indicate non-adherence or a secondary cause.

Vitamin D and Calcium: The Foundation Layer

No monitoring schedule works without adequate calcium and vitamin D. The National Academy of Medicine recommends 1,200 mg of calcium daily for women over 50 (ideally from diet) and 600 to 800 IU of vitamin D daily, with many osteoporosis specialists supplementing to 1,500 to 2,000 IU to maintain blood levels above 30 ng/mL.

A serum 25-hydroxyvitamin D below 20 ng/mL is associated with secondary hyperparathyroidism that accelerates bone loss and can blunt the response to antiresorptives. Correct vitamin D deficiency before or concurrent with starting any osteoporosis medication.

Pregnancy, Lactation, and Contraception Considerations

Most medications used for postmenopausal osteoporosis are not relevant to pregnancy by virtue of the patient population. Postmenopausal women are not pregnant. But two important groups require specific counseling.

Premenopausal Women with Secondary Osteoporosis

Women of reproductive age can develop osteoporosis from glucocorticoid use, eating disorders, PCOS with hypothalamic dysfunction, or lactation-associated osteoporosis. In these women, treatment choices differ substantially.

Bisphosphonates: FDA Pregnancy Category D (now PLLR "known risk"). Bisphosphonates incorporate into bone and can persist for years. Animal studies show fetal skeletal toxicity. Any premenopausal woman started on a bisphosphonate should be counseled that pregnancy within the treatment period carries unknown but potential fetal risk. Reliable contraception is mandatory during bisphosphonate therapy in women who could become pregnant.

Denosumab: Contraindicated in pregnancy. Denosumab's FDA label warns of fetal harm based on animal data showing skeletal, lymph node, and immune system abnormalities. Pregnancy must be excluded before each injection, and women of childbearing potential must use effective contraception during treatment and for at least 5 months after the last dose.

Teriparatide and Abaloparatide: Both are contraindicated in pregnancy. Animal data show skeletal and other abnormalities. Neither should be used in women who may become pregnant.

Romosozumab: Contraindicated in pregnancy. Effective contraception is required during the 12-month treatment course.

Lactation-Associated Osteoporosis

A distinct and underrecognized condition: some women develop vertebral fractures during or immediately after prolonged breastfeeding due to calcium mobilization from the skeleton. A 2015 review in Osteoporosis International reported that BMD losses during lactation average 3 to 5 percent at the lumbar spine, typically recovering within 6 to 12 months after weaning without pharmacologic intervention. Monitoring in this group means serial DEXA every 6 to 12 months if fractures have occurred, with close calcium and vitamin D support. Pharmacologic treatment during lactation is generally avoided because no drug has adequate safety data for the nursing infant.

Who This Monitoring Schedule Is Right For (and Who Needs Something Different)

This framework applies to postmenopausal women with confirmed osteoporosis (T-score at or below -2.5) or high fracture risk. Adjust the schedule in these specific scenarios:

Women with prior fragility fracture: DEXA annually for the first 2 years on therapy, then every 2 years if stable. FRAX recalculated at each visit. These women are at highest imminent fracture risk; the 2-year risk after a vertebral fracture is particularly high, and the IOF/ESCEO 2019 guidelines recommend treating them as "very high risk" with anabolic-first sequencing when possible.

Women on chronic glucocorticoids (prednisone equivalent 5 mg/day for over 3 months): DEXA at the start of glucocorticoid therapy, then annually. The ACR 2022 Guideline for Prevention and Treatment of Glucocorticoid-Induced Osteoporosis recommends starting a bisphosphonate at initiation of glucocorticoids for women already at moderate or high fracture risk, not waiting for a low T-score.

Women with PCOS: Hyperandrogenism in PCOS may be partially protective of bone, but women with the lean, hypothalamic-dysfunction phenotype of PCOS often have low estrogen and low BMD. Monitoring in this group should follow the same risk-stratified approach as perimenopausal women.

Women who have had bariatric surgery: Calcium malabsorption after Roux-en-Y gastric bypass markedly accelerates bone loss. DEXA at 2 years post-surgery and annually if osteopenia is found is the recommendation from ASMBS and AACE bariatric guidelines.

Women on aromatase inhibitors for breast cancer: Aromatase inhibitors (AIs) suppress estrogen to near-zero in postmenopausal women and cause 2 to 3 percent BMD loss per year. The ASCO 2019 guideline on bone health in cancer survivors recommends DEXA at baseline and every 2 years during AI therapy, with bisphosphonate initiation if T-score drops below -2.0 or fracture occurs.

The Evidence Gap: What We Do Not Know Yet

Women have been the primary subjects in osteoporosis trials, which is an exception to the broader pattern of female underrepresentation in clinical research. But important gaps remain. Most large fracture endpoint trials enrolled women over 65 with established osteoporosis; data are thinner for women in the 50 to 64 perimenopausal window who are losing bone rapidly but have not yet hit T-score thresholds.

The optimal monitoring interval during a drug holiday is directly studied in the FLEX trial (alendronate) and the HORIZON extension, but data on what happens to non-white women, women with very low BMI, or women with concurrent thyroid disease are extrapolated rather than directly measured. Bone turnover marker thresholds for treatment decisions are also extrapolated from populations that were predominantly white and European.

A 2021 meta-analysis in JAMA found that bisphosphonate efficacy in preventing non-vertebral fractures was strong across most subgroups, but confidence intervals widened considerably in women under 65 and in those with T-scores between -1.5 and -2.5, the osteopenia range where many real-world treatment decisions are made.

"We do not have strong data on optimal monitoring intervals for women who start treatment in their early fifties," said Dr. Clifford Rosen, senior scientist at the Maine Medical Center Research Institute and co-author of multiple Endocrine Society guidelines. Decisions in that group currently rest on expert consensus more than randomized trial evidence.

Practical Monitoring Checklist by Year

| Timepoint | Action | |---|---| | Diagnosis / treatment start | DEXA (lumbar spine + hip), VFA if indicated, baseline labs (vitamin D, calcium, CMP, TSH), FRAX | | 3-6 months on treatment | Serum CTX or P1NP (optional, to confirm adherence and response) | | 1-2 years on treatment | Repeat DEXA; adjust therapy if inadequate response (<least significant change in BMD) | | Every 6 months (denosumab only) | Serum calcium, renal function before each injection | | Annually | Serum 25-OH vitamin D, calcium, renal function; FRAX if untreated or on drug holiday | | 3-5 years oral bisphosphonate | Reassess for drug holiday; DEXA at start of holiday | | Every 2-3 years during drug holiday | DEXA; restart if T-score falls or fracture occurs | | After stopping denosumab | DEXA at 6-12 months; transition to bisphosphonate immediately |